Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

Unified Inclusion Criteria:

• Participants aged 1-12 years ;
• The subjects and/or guardians can understand and voluntarily sign the informed consentform (For subjects aged 8-12 years, both subjects and guardians need to sign theinformed consent form) and be able to follow all research procedures;
• Proven legal identity. Special Inclusion Criteria for each study: Inclusion criteria of the study population for immunogenicity and safety evaluation ofvaricella vaccine:
• Be able to participate in the whole process of vaccination and blood collection;
• Healthy children aged 1-3 years with no history of varicella vaccination;
• Healthy children aged 4-6 years with a history of 1 dose of varicella vaccine. Inclusion criteria for investigation of varicella antibody level:
• Healthy people aged 0-59 years and participate voluntarily for the study;
• Have no serious chronic disease or acute disease; Inclusion criteria of the study population for safety evaluation of varicella vaccine massvaccination:
• Participants aged 1-3 years with no history of varicella vaccination;
• Participants aged 4-12 years with no history of varicella vaccination or with ahistory of 1 dose of varicella vaccine. Inclusion criteria of study population for protective effect of varicella vaccine afterexposure:
• Children aged 1-12 years exposed to varicella outbreaks;
• History with no varicella or shingles; Inclusion criteria of study population for etiological study on the pathogenic strains ofvaricella cases:
• Clinical cases of varicella consent for herpes zoster or pharyngeal swab collection.

Exclusion Criteria:

• History of 2 doses of varicella vaccination;
• Previous history of varicella or herpes zoster (not applicable to investigation ofvaricella antibody level);
• History of severe allergic reactions to vaccines (e.g.acute anaphylaxis, angioneuroticedema, dyspnea, etc.);
• Suffering from acute disease or acute episode of chronic disease;
• Any confirmed or suspected immunodeficiency disease, including human immunodeficiencyvirus (HIV) infection;
• Axillary temperature >37.0°C;
• Receipt of other investigational drugs in the past 30 days;
• Receipt of attenuated live vaccines in the past 28 days;
• Receipt of inactivated or subunit vaccines in the past 7 days;
• According to the investigator's judgment, the subject has any other factors that arenot suitable for participating in the clinical trial.